{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:01:32Z","timestamp":1792119692605,"version":"4.4.0"},"reference-count":21,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Cutan Pathol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>PRAME (PReferentially expressed Antigen in MElanoma) has shown utility in distinguishing melanoma from benign melanocytic lesions, but knowledge of its expression pattern in intermediate melanocytic and spitzoid proliferations is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Immunohistochemical expression of PRAME was examined in 112 melanocytic proliferations with intermediate histopathologic or spitzoid features.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Any intensity of nuclear PRAME staining in at least 60% of lesional melanocytes was determined as the best threshold for diffuse staining in this cohort. Nearly all non\u2010spitzoid melanomas (23\/24; 95.8%) demonstrated diffuse PRAME expression. PRAME was completely negative in 95.6% (43\/45) of mitotically\u2010active nevi, traumatized nevi, nevi with persistent\/recurrent features, and dysplastic nevi. Most Spitz nevi (15\/20) and atypical Spitz tumors (10\/13) entirely lacked PRAME expression. One Spitz nevus, one atypical Spitz tumor, and one spitzoid melanoma (1\/2) demonstrated diffuse PRAME expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although diffuse PRAME expression is generally limited to malignant melanoma, benign Spitz nevi and atypical Spitz tumors can infrequently express diffuse PRAME. PRAME immunohistochemistry can be useful in the evaluation of atypical melanocytic proliferations with intermediate histopathologic features but should be interpreted with caution in the setting of spitzoid neoplasms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/cup.13818","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T07:36:46Z","timestamp":1595489806000},"page":"1123-1131","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":109,"title":["<scp>PRAME<\/scp>\n                    expression in melanocytic proliferations with intermediate histopathologic or spitzoid features"],"prefix":"10.1111","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3816-1542","authenticated-orcid":false,"given":"Shyam S.","family":"Raghavan","sequence":"first","affiliation":[{"name":"Department of Pathology University of Virginia School of Medicine  Charlottesville Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2537-1081","authenticated-orcid":false,"given":"Jennifer Y.","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology Stanford University School of Medicine  Stanford California USA"},{"name":"Department of Dermatology Stanford University School of Medicine  Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Kwok","sequence":"additional","affiliation":[{"name":"Department of Pathology Stanford University School of Medicine  Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4436-2471","authenticated-orcid":false,"given":"Kerri E.","family":"Rieger","sequence":"additional","affiliation":[{"name":"Department of Pathology Stanford University School of Medicine  Stanford California USA"},{"name":"Department of Dermatology Stanford University School of Medicine  Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto A.","family":"Novoa","sequence":"additional","affiliation":[{"name":"Department of Pathology Stanford University School of Medicine  Stanford California USA"},{"name":"Department of Dermatology Stanford University School of Medicine  Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9099-7227","authenticated-orcid":false,"given":"Ryanne A.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Pathology Stanford University School of Medicine  Stanford California USA"},{"name":"Department of Dermatology Stanford University School of Medicine  Stanford California USA"},{"name":"Department of Pathology Veterans Affairs Palo Alto Health Care System  Palo Alto California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,9,10]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80426-4"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/cup.12475"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2015.11.035"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2013.244"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cjp2.16"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2016.12.006"},{"issue":"18","key":"e_1_2_5_8_1","first-page":"4090","article-title":"Heterogeneous expression of the tumor\u2010associated antigens RAGE\u20101, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T\u2010cell\u2010based immunotherapies?","volume":"58","author":"Neumann E","year":"1998","journal-title":"Cancer Res"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0813"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.08.120"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9977"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.2217\/bmm.12.65"},{"issue":"4","key":"e_1_2_5_13_1","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1136\/esmoopen-2016-000068","article-title":"Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study","volume":"1","author":"Gutzmer R","year":"2016","journal-title":"ESMO Open"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2017.0729"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001134"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001393"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000198"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2014.2497"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2016.70"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001492"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3182753de6"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000001217"}],"container-title":["Journal of Cutaneous Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcup.13818","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cup.13818","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cup.13818","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cup.13818","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T21:03:21Z","timestamp":1693861401000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cup.13818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1111\/cup.13818"],"URL":"https:\/\/doi.org\/10.1111\/cup.13818","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.738376140.793581038","asserted-by":"object"}]},"ISSN":["0303-6987","1600-0560"],"issn-type":[{"value":"0303-6987","type":"print"},{"value":"1600-0560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,10]]},"assertion":[{"value":"2020-04-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}